glp 1 agonist cardioprotective The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Semaglutide Shows Secondary Cardiovascular Prevention
Description
Should a drug with the FDAs most serious warning be this easy to access for 1.4 billion people
And eventually, it may be evidence payers, clinicians, employers, and patients all start asking for.
Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.
A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year
What Is A GLP-1 Agonist
This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides
